Home

Reid M Huber

CIK 1607052 · EVP, Chief Scientific Officer · last filed 2026-06-10

Reid M Huber is an EVP, Chief Scientific Officer who has filed 47 SEC Form 4 insider transactions across 5 companies since 2014. The most recent filing, for RAPP, was dated Jun 10, 2026. Across all open-market trades the lifetime net is −$9.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $5.2M across reported positions. 26 SEC filings were submitted jointly with INCYTE CORP.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$5.21M

Companies

5

Total Filings

47

Lifetime Open-Market Net

-$9.12M

Filer Profile

Reported Address
C/O THIRD ROCK VENTURES, LLC
201 BROOKLINE AVENUE, SUITE 1401
BOSTON, MA 02215
Related Filers
INCYTE CORP — 26 joint filings, latest 2018-07-18
Tango Therapeutics, Inc. — 3 joint filings, latest 2023-06-08
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
RAPP Director 20,400 $43.62 $889.8K $499.4K 3 2026-06-10
CARGO Therapeutics, Inc. (CRGX) Delisted Director — $4.47 — $0 4 2025-08-19
TNGX Director 5,000 $23.78 $118.9K $0 2 2023-06-08
BELLICUM PHARMACEUTICALS, INC (BLCM) Delisted Director 146,951 $0.07 $11.0K $0 13 2023-01-20
INCY EVP, Chief Scientific Officer 34,571 $121.47 $4.20M -$9.61M 25 2018-07-18

Recent Filings

47 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-10 RAPP Grant (A) — $0 EDGAR
2025-09-15 RAPP Buy (P) +20,400 $499.4K EDGAR
2025-08-19 CARGO Therapeutics, Inc. (CRGX) Delisted Disp (D) — $0 EDGAR
2025-06-20 CARGO Therapeutics, Inc. (CRGX) Delisted Grant (A) — $0 EDGAR
2025-06-18 RAPP Grant (A) — $0 EDGAR
2024-06-06 CARGO Therapeutics, Inc. (CRGX) Delisted Grant (A) — $0 EDGAR
2023-11-13 CARGO Therapeutics, Inc. (CRGX) Delisted Grant (A) — $0 EDGAR
2023-06-08 TNGX Grant (A) +5,000 $0 EDGAR
2023-01-20 BELLICUM PHARMACEUTICALS, INC (BLCM) Delisted Exer (M) +80,968 $0 EDGAR
2023-01-05 BELLICUM PHARMACEUTICALS, INC (BLCM) Delisted Exer (M) +87,196 $0 EDGAR
Showing 1–10 of 47
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.